GlassScriptPhysician profile
Brittany Taylor Hamby
NPI 1023325180
$7,030.58
in general payments reported to CMS, 2019-2025
26 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,300 · 2022: $1,129 · 2023: $1,566 · 2024: $1,337 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,368 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,368.42 |
| Education | $233.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,301.22 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,004.83 | 2021-2025 | Dupixent |
| Csl Behring | $834.74 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $720.35 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $483.05 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Glaxosmithkline, LLC. | $479.61 | 2021-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Grifols USA, LLC | $277.00 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Pfizer INC. | $242.63 | 2021-2025 | |
| Blueprint Medicines Corporation | $238.63 | 2023-2024 | Ayvakit |
| Biocryst US Sales Co., LLC | $237.40 | 2021-2025 | Orladeyo |
| Amgen INC. | $182.24 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $173.30 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $155.23 | 2025 | |
| Abbvie INC. | $148.12 | 2021-2023 | |
| Genentech USA, INC. | $103.59 | 2021-2025 | Xolair |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $87.49 | 2023-2024 | Cutaquig |
| Aimmune Therapeutics, INC. | $71.25 | 2021-2022 | |
| Pharming Healthcare, INC. | $62.78 | 2021-2025 | Ruconest |
| Seqirus USA INC | $54.64 | 2023-2024 | Fluad, Flucelvax, Flucelvax Quadrivalent |
| Optinose US, INC. | $49.36 | 2025 | |
| Kaleo, INC. | $37.96 | 2023-2024 | Auvi-Q |
| Uswm, LLC | $24.00 | 2021 | |
| Cycle Pharmaceuticals INC | $17.80 | 2024 | Sajazir |
| Galderma Laboratories, L.P. | $15.49 | 2025 | Nemluvio |
| Covis Pharma Gmbh | $14.75 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Hamby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.